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Received September 22, 2014; accepted February 6, 2015AbstractBackground: In most institutions, locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy followed by surgery 6e8 weeks
later, allowing time for tumor response and recovery from chemoradiotherapy-related toxicities. In our hospital, we continuously administer
chemotherapy after the completion of chemoradiotherapy, until 2 weeks before surgery for most patients.
Methods: This was a retrospective study. Patients received a diagnosis of adenocarcinoma of the rectum at our hospital between January 2003
and December 2008 and received neoadjuvant chemoradiotherapy and curative surgery. Chemoradiotherapy consisted of continuous infusion of
225 mg/m2 5-fluorouracil, 5 days per week. Radiation therapy was delivered at 1.8 Gy per day, 5 days per week for 5e6 weeks (median radiation
dose, 50.4 Gy). Chemotherapy was continued until 2 weeks before surgery, and surgery was performed 6e8 weeks after completion of
chemoradiotherapy.
Results: The study included 119 patients (median age, 61 years; range, 24e84 years). Twenty-nine patients (24.4%) had a complete response and
65 (54.6%) had a partial response. Over a median follow-up duration of 52 months, 10 patients experienced local recurrence and 18 had distant
metastasis. The 5-year overall and disease-free survival rates were 80.6% and 72.9%, respectively. Grade 3e4 toxicity only occurred in 14
patients (11.8%).
Conclusion: Continued chemotherapy with 5-fluorouracil after completing neoadjuvant chemoradiotherapy until 2 weeks before surgery for
locally advanced rectal cancer results in a good pathological control rate, with low toxicity. Patients who achieved a complete pathological
response had a better long-term oncological outcome than those who did not.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assfor locally advanced rectal cancer (defined as T3 or node-
positive rectal cancer). Preoperative CRT is associated with
a lower local recurrence rate and general toxicities than
postoperative CRT.1e3 Neoadjuvant CRT usually results in a
reduced tumor size, increased tumor mobility, and histopath-
ologic downstaging, with correspondingly improved long-term
oncologic outcomes.4 Approximately 15e20% of patients
have a pathological complete response (pCR) at the time of
surgery,5e7 although the likelihood of a pCR may be related toociation. All rights reserved.
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the radiotherapy dose.
In most institutions, locally advanced rectal cancer is
generally treated with neoadjuvant CRT followed by surgery,
~6e8 weeks later, to allow for a tumor response to CRT and
recovery from CRT-related toxicity. In our hospital, we
continue to administer chemotherapy after the completion of
CRT until 2 weeks before surgery for locally advanced rectal
cancer. Here, we report the oncological outcome, pathological
complete response rate, and toxicities associated with this
strategy.
2. Methods2.1. Data sourceWe retrospectively reviewed the medical records of pa-
tients in whom adenocarcinoma of the rectum was diagnosed
(tumor located within 12 cm from the anal verge) who
received neoadjuvant CRT in our hospital between January
2003 and December 2008. Patients with tumor metastasis or
unresectable tumors, those who only underwent local exci-
sion, and those who achieved a clinical complete response
under observation alone were excluded. The rectal adeno-
carcinoma diagnosis was based on sigmoidoscopy biopsy. T
staging was scored by transrectal ultrasonography or mag-
netic resonance imaging (MRI), and N staging was scored by
pelvic computed tomography (CT). Distant metastasis was
evaluated using an abdominal CT scan and chest X-ray film
for all patients. Clinical data including age, sex, Eastern
Cooperative Oncology Group performance status, operative
method, tumor recurrence, tumor distance from the anal
verge, pretreatment clinical tumor stage and size, histologic
grade, radiotherapy dose, chemotherapy toxicities, preopera-
tive clinical stage, postoperative pathological stage, site of
tumor recurrence, survival status, and duration of follow-up
were analyzed.
The treatment program is shown in Fig. 1. All patients were
treated with 5-fluorouracil (5-FU) continuous infusion at a
dose of 225 mg/m2, 5 days per week, concurrent with radio-
therapy. Radiation therapy was delivered at 1.8 Gy per day, 5
days per week for 5e6 weeks, and the median radiation dose
was 50.4 Gy (range, 43.2e65.5 Gy). Chemotherapy wasFig. 1. Treatment schedule for patients included in this study.continued until 2 weeks before surgery, and the patient un-
derwent surgery within 6e8 weeks after finishing radio-
therapy. The clinical response was evaluated by post-CRT CT,
sigmoidoscopy, and digital rectal examination. After surgery,
planned adjuvant treatment was a 5-FU based chemotherapy
regimen.2.2. Statistical analysesWe compared the general characteristics between groups
with and without pCR. We analyzed differences with respect
to specific clinical factors according to whether patients had
a complete response using Student t test, Yates' correction
and Fisher's exact test. We compared the recurrence rate
between groups with and without pCR using Fisher's exact
test.
Overall survival was defined as the time from the beginning
of CRT to the date of the last follow-up visit or death. Disease-
free survival was defined as the time from surgery to the date
of death, last follow-up visit, or treatment failure (local or
distant recurrence). Local recurrence was defined as tumor
recurrence in the pelvis, perineum, or anastomosis site. Distant
metastasis was defined as tumor recurrence outside the pelvis.
The follow-up duration was defined as the time from surgery
to the last follow-up visit or any type of event. We used the
KaplaneMeier survival method to compare disease-free and
overall survival for patients with and without pCR, and log-
rank test to identify significant differences. All analyses
were performed using GraphPad Prism Version 5 (GraphPad
Software, San Diego, CA, USA). A p value <0.05 was
considered statistically significant.
3. Results
Between January 2003 and December 2008, 127 patients
were included in our study; eight patients did not complete the
full course of CRT (6 due to CRT intolerance and 2 due to
disease progression during CRT). Finally, a total of 119 pa-
tients were included in the analysis. The characteristics of all
119 patients are summarized in Table 1. Seventy-four patients
were men and 45 were women, with a median age of 61 years
(range, 24e84 years). Thirty-six patients (30.3%) underwent
transrectal ultrasonography for clinical T staging and 83
(69.7%) underwent MRI for clinical T staging. The preoper-
ative clinical stage of the patients was stage II in 41 cases
(34.5%) and stage III in 78 cases (65.5%), and the median
tumor size was 2.8 cm (range, 0.8e12 cm). After neoadjuvant
CRT, all patients underwent surgery, which involved lower
anterior resection in 81 cases (31 cases with protective ileos-
tomy), abdominoperineal resection in 37 cases, and Hartmann
procedure in one case. Of 67 patients with a low rectal tumor
(tumor located  5 cm from the anal verge), 30 patients
(44.8%) had sphincter preservation. The final pathological
stage revealed complete remission in 29 cases (24.4%), stage
0 (ypTisN0M0) disease in one case (0.8%), stage I disease in
31 (26.1%), stage II disease in 31 (26.1%), and stage III dis-
ease in 27 (22.7%). Total downstaging was observed in 94
Table 1
Patient characteristics.
Patient characteristics n (%)
Age (y)
Median (range) 61 (24e84)
Sex
Male 74 (62.2)
Female 45 (37.8)
Performance status
0 74 (62.2)
1 34 (28.6)
2 11 (9.2)
Tumor location
Lower (5 cm) 67 (56.3)
Middle (>5e 10 cm) 48 (40.3)
Upper (>10e 12 cm) 4 (3.4)
Pre-CRT clinical stage
II 41 (34.5)
III 78 (65.5)
Pre-CRT T stage
T2 18 (15.1)
T3 95 (79.8)
T4 6 (5)
Pre-CRT N stage
N0 41 (34.4)
N1 61 (51.3)
N2 17 (14.3)
Tumor size (cm)
Median (range) 2.8 (0.8e12)
CRT ¼ chemoradiotherapy.
Table 2
Comparison of the general characteristics of complete responders and non-
complete responders to chemoradiotherapy.
Complete
responders (n ¼ 29)
Noncomplete
responders (n ¼ 90)
p
Age (y) 63.6 ± 15.7 60.5 ± 15.8 0.353a
Sex 0.99b
Male 18 (62.1) 56 (62.2)
Female 11 (37.9) 34 (37.8)
Distance from the anal
verge (cm)
5.6 ± 2.9 6.1 ± 2.8 0.403a
Tumor size (mm) 28.6 ± 18.4 34.6 ± 20.7 0.163a
Pre-CRT clinical stage 0.999b
Stage II 10 (34.5) 31 (34.4)
Stage III 19 (65.5) 59 (65.6)
Pre-CRT T stage 0.915c
T2 5 (17.2) 13 (14.4)
T3 23 (79.3) 72 (80)
T4 1 (3.4) 5 (5.6)
Pre-CRT N stage 0.431c
N0 10 (34.5) 31 (34.4)
N1 17 (58.6) 44 (48.9)
N2 2 (6.9) 15 (16.7)
Histologic differentiation 0.405c
Well 3 (10.3) 6 (6.7)
Moderate 25 (86.2) 73 (81.1)
Poor 1 (3.4) 11 (12.2)
Curative surgery
(R0 resection)
29 (100) 88 (97.8) 0.999c
Sphincter preservation 21 (72.4) 60 (66.7) 0.728b
Data are presented as n (%) or mean ± SD.
CRT ¼ chemoradiotherapy.
a Student t test.
b Yates' correction.
c Fisher's exact test.
Table 3
Comparison of the oncological outcomes in complete responders and non-
complete responders to chemoradiotherapy with continued chemotherapy.
Complete responders Noncomplete responders pa
Local recurrence 0 10 (11.1) 0.116
Distant metastasis 0 18 (20) 0.006
Overall recurrence 0 24 (26.7) 0.001
Data are presented as n (%).
a Fisher's exact test.
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response and 65 (54.6%) had a partial response. Upstaging
occurred in five patients after surgery. Of the 29 patients with
complete response, 21 (72.4%) received adjuvant chemo-
therapy. Of the 90 patients with no complete response, 80
(88.9%) received adjuvant chemotherapy. Of the 101 patients
who received adjuvant chemotherapy, 94 (93.1%) completed
the planned number of treatment cycles.
The median follow-up time was 52 months (range, 7e100
months), during which local recurrence occurred in 10 (8.4%)
patients and distant metastasis occurred in 18 (15.1%). The 5-
year overall and disease-free survival rates were 80.6% and
72.9%, respectively. Four patients had concomitant local
recurrence and distant metastasis.
As shown in Table 2, neither age ( p ¼ 0.353), sex
( p ¼ 0.99), tumor location ( p ¼ 0.403), tumor size
( p ¼ 0.163), pre-CRT clinical staging ( p ¼ 0.999), pre-CRT T
staging ( p ¼ 0.915), pre-CRT N staging ( p ¼ 0.431),
sphincter preservation ( p ¼ 0.728), nor histologic type
( p ¼ 0.405) were significantly different between patients who
did or did not achieve a complete response.
Fewer patients who achieved a complete response had local
recurrence (0% vs. 11.1%, p ¼ 0.116), distant metastasis (0%
vs. 20%, p ¼ 0.006) or any type of recurrence (0% vs. 26.7%,
p ¼ 0.001) compared to those who failed to achieve a com-
plete response (Table 3). The 5-year disease-free survival rate
was 96.6% for the pCR group and 65.6% for the non-pCR
group [hazard ratio (HR): 5.306; 95% confidence interval(CI): 1.283e6.202; p ¼ 0.009; Fig. 2]. The 5-year overall
survival rate was 96.6% for the pCR group and 75.8% for the
non-pCR group (HR: 2.379; 95%CI: 0.634e6.507; p ¼ 0.069;
Fig. 3).3.1. ToxicityThe toxicity events are listed in Table 4. The most common
adverse events related to CRT were leukopenia (30.3%) and
diarrhea (25.2%). Overall, Grade 3e4 toxicities developed in
14 patients (11.8%), of whom Grade 4 leukopenia developed
in one, Grade 4 diarrhea in one, Grade 3 leukopenia in six,
Grade 3 diarrhea in one, Grade 3 anemia in two, a Grade 3
dermatologic complication in two, and Grade 3 vomiting in
one.
Fig. 2. Cumulative disease-free survival of patients who achieved a complete response (“Complete responders”) and those who failed to achieve a complete
response (“Noncomplete responders”) after chemoradiotherapy. Cumulative proportion surviving at 5 years, Complete responders: 0.966. Noncomplete responders:
0.656. CI ¼ confidence interval; HR ¼ hazard ratio.
Fig. 3. Cumulative overall survival of patients who achieved a complete response (“Complete responders”) and those who failed to achieve a complete response
(“Noncomplete responders”) after chemoradiotherapy. Cumulative proportion surviving at 5 years, Complete responders: 0.966. Noncomplete responders: 0.758.
CI ¼ confidence interval; HR ¼ hazard ratio.
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Currently, neoadjuvant CRT with 5-FU is widely used for
treating locally advanced rectal cancer in order to achieveTable 4
Toxicity events in patients.
Toxicity Grades 1e2 Grades 3e4
Gastrointestinal
Diarrhea 28 (23.5) 2 (1.7)
Nausea 22 (18.5) 0
Vomiting 12 (10) 1 (0.8)
Mucositis 8 (6.7) 0
Hematologic
Anemia 16 (13.4) 2 (1.7)
Leukopenia 29 (24.4) 7 (5.9)
Thrombocytopenia 14 (11.8) 0
Dermatologic 15 (12.6) 2 (1.7)
Data are presented as n (%).tumor downstaging and shrinkage, thereby increasing the
likelihood of curative surgical resection and reducing the risk
of local recurrence.8,9 Many studies have found that patients
with pCR after CRT are less likely to have local or distant
recurrence, and survive for longer than those with non-
complete response.10e12 Therefore, conventional CRT has
been modified in a number of studies, for example, by
including additional chemotherapeutic agents, extending the
interval between CRT and surgery, and adding continued
chemotherapy in the period between CRT and surgery. Addi-
tional chemotherapeutic agents that have been studied in this
context include oxaliplatin13,14 and cetuximab.15,16 These
resulted in a pCR rate of 8e19%, which is lower than the
24.4% observed in our study. Although adding irinotecan17
resulted in a higher pCR rate of 26%, the incidence of acute
Grade 3e4 toxicity was as high as 42%, and hence, this
therapy cannot be well tolerated by most patients. None of
these studies convincingly showed that adding these
479P.-K. Chang et al. / Journal of the Chinese Medical Association 78 (2015) 475e480chemotherapy agents can improve the pCR, and the combi-
nation of two or more chemotherapy agents may result in
higher toxicity rates and a higher cost.
The results of additional chemotherapy during the resting
period after CRT have also been reported. Garcia-Aguilar et
al18 reported a nonrandomized prospective trial comparing one
group of patients who underwent CRT consisting of 5-FU
followed by surgery 6 weeks later, with another group
treated with an additional two cycles of modified FOLFOX-6
in the 4 weeks following the completion of CRT and then
surgery 3e5 weeks later. This study concluded that additional
chemotherapy after CRT was well tolerated and may increase
the pCR rate (18% vs. 25%), although this difference was not
statistically significant. Furthermore, surgery was delayed for
patients undergoing additional chemotherapy, and it is there-
fore possible that the increased pCR rate was actually attrib-
utable to a longer CRT-to-surgery interval. The oncological
outcome was also not reported in this study.
Another additional chemotherapy regimen after CRT
completion, investigated by Habr-Gama et al,19 consisted of
three extra cycles of bolus 5-FU. Their study included 29
patients, of whom 14 (48%) had a clinical complete response
for at least 12 months and five (17%) had ypT0 after local
excision. The overall complete response rate was 65%. How-
ever, none of the patients underwent TME, and occult cancer
might not have been detected during the median follow-up
period of 24 months. Another complication is that 17% of
patients had stage I disease, which may have contributed to the
high pCR rate.
In our study, continuously administered chemotherapy with
5-FU after the completion of radiotherapy until 2 weeks before
surgery for locally advanced rectal cancer resulted in a pCR
rate of 24.4%, which is higher than that obtained using con-
ventional 5-FU-based CRT (15e20%).5e7 The high pCR rate
might be attributable to the prolonged exposure of irradiated
tumor cells to chemotherapy. Furthermore, only 14 patients
(11.8%) experienced Grade 3e4 toxicity and most tolerated
the treatment well, with good treatment compliance. When
compared to adding chemotherapeutic agents to CRT, such as
oxaliplatin14 or irinotecan,17 which resulted in an incidence of
Grade 3e4 toxicity >20%, the toxicity associated with our
approach was more tolerable.
In the current study, the 5-year disease-free survival rate
(96.6% vs. 65.6%, p ¼ 0.009) and 5-year overall survival rate
(96.6% vs. 75.8%, p ¼ 0.069) were higher in the complete
response group than in the noncomplete response group.
Several previous studies reported that patients with a pCR
after CRT had better long-term outcomes than those who did
not achieve a pCR,10e12 although another study found similar
outcomes between these patient groups.20 Our study also
confirmed that patients with a pCR more often achieved 5-year
disease free and overall survival. Overall survival did not
differ significantly between pCR and non-pCR groups in our
study, which might be due to the higher median age (61 years)
and the relatively small size of the former group. The local
recurrence rate, distant metastasis rate, and overall recurrence
rate were lower in pCR group. These findings further supportthe importance of achieving a pCR in order to improve long-
term oncological outcome.
There are a number of limitations to our study. First,
although the pCR rate was higher in our study than in most
studies reported in the literature, the benefit of the continued
chemotherapy was difficult to interpret because of the absence
of a control group. Second, owing to the retrospective design
of the study, it is possible that some data were missing and that
some cases of disease relapse had not been recorded because
of poor communication. Furthermore, the radiation dose and
chemotherapy dose cannot be well controlled in a retrospec-
tive study. Finally, the study had only a small sample size. A
multicenter randomized prospective study is needed to vali-
date our findings.
In conclusion, continued chemotherapy with 5-FU after the
completion of neoadjuvant CRT until 2 weeks before curative
surgery for locally advanced rectal cancer results in only a low
level of toxicity and a good pCR rate. Patients who had a pCR
after CRT had better long-term oncological outcomes.
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